[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488618":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":11,"locations":24,"responsibleParty":190,"collaborators":11,"id":192,"slug":193,"hasResults":194,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":11,"eligibilityCriteria":198,"healthyVolunteers":194,"sex":199,"minAge":200,"maxAge":201,"enrollmentInfo":202,"targetDuration":11,"studyType":205,"phases":206,"briefSummary":209,"conditions":210,"keywords":11,"overallStatus":27,"whyStopped":11,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":225},{"fullName":5,"class":6},"USWM, LLC (dba US WorldMeds)","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Afamitresgene autoleucel","EXPERIMENTAL",null,[13],"Genetic: Afamitresgene autoleucel",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":11},"GENETIC","Single infusion of afamitresgene autoleucel Dose: For subjects ≥10 kg to \\\u003C40 kg: starting dose of 0.025 - 0.200 x 10'9 transduced cells\u002Fkg. For subjects ≥40 kg 1.0x109 to 10x109 transduced by a single intravenous infusion",[9],[20],{"name":21,"affiliation":22,"role":23},"Fiorella Iglesias Cardenas, MD","Memorial Sloan Kettering Kids","PRINCIPAL_INVESTIGATOR",[25,47,64,78,99,111,127,143,160,173],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Stanford University","RECRUITING","Palo Alto","California","94305","United States","US",{"type":34,"coordinates":35},"Point",[36,37],-122.14302,37.44188,{"lat":37,"lon":36},[40,45],{"name":41,"role":42,"phone":43,"phoneExt":11,"email":44},"Amy Li","CONTACT","650-788-6811","ali4@stanford.edu",{"name":46,"role":23,"phone":11,"phoneExt":11,"email":11},"Sneha Ramakrishna, MD",{"facility":48,"status":27,"city":49,"state":50,"zip":51,"country":31,"countryCode":32,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"National Institutes of Health","Bethesda","Maryland","20892",{"type":34,"coordinates":53},[54,55],-77.10026,38.98067,{"lat":55,"lon":54},[58,62],{"name":59,"role":42,"phone":60,"phoneExt":11,"email":61},"Kane Kaosaard","301-204-9057","kane.kaosaard@nih.gov",{"name":63,"role":23,"phone":11,"phoneExt":11,"email":11},"John Glod, MD",{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":31,"countryCode":32,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Dana Farber Cancer Institute","NOT_YET_RECRUITING","Boston","Massachusetts","10065",{"type":34,"coordinates":71},[72,73],-71.05977,42.35843,{"lat":73,"lon":72},[76],{"name":77,"role":23,"phone":11,"phoneExt":11,"email":11},"Natalie Collins, MD",{"facility":79,"status":27,"city":80,"state":81,"zip":82,"country":31,"countryCode":32,"cosmosGeoPoint":83,"geoPoint":87,"contacts":88},"Washington University","St Louis","Missouri","63110",{"type":34,"coordinates":84},[85,86],-90.19789,38.62727,{"lat":86,"lon":85},[89,93,97],{"name":90,"role":42,"phone":91,"phoneExt":11,"email":92},"Tina Primeau, BA","314-454-2147","tprimeau@wustl.edu",{"name":94,"role":42,"phone":95,"phoneExt":11,"email":96},"Catie Knoerle, BA","314-747-1828","knoerlec@wustl.edu",{"name":98,"role":23,"phone":11,"phoneExt":11,"email":11},"Amy Armstrong, MD",{"facility":22,"status":66,"city":100,"state":100,"zip":69,"country":31,"countryCode":32,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"New York",{"type":34,"coordinates":102},[103,104],-74.00597,40.71427,{"lat":104,"lon":103},[107,110],{"name":21,"role":42,"phone":108,"phoneExt":11,"email":109},"212-639-6649","iglesiaf@mskcc.org",{"name":21,"role":23,"phone":11,"phoneExt":11,"email":11},{"facility":112,"status":66,"city":113,"state":114,"zip":115,"country":31,"countryCode":32,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Duke University School of Medicine","Durham","North Carolina","27710",{"type":34,"coordinates":117},[118,119],-78.89862,35.99403,{"lat":119,"lon":118},[122,126],{"name":123,"role":42,"phone":124,"phoneExt":11,"email":125},"Kris Mahadeo, MD","919-668-1180","kris.mahadeo@duke.edu",{"name":123,"role":23,"phone":11,"phoneExt":11,"email":11},{"facility":128,"status":27,"city":129,"state":130,"zip":131,"country":31,"countryCode":32,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Cincinnati Children's Hospital Medical Center","Cincinnati","Ohio","45229",{"type":34,"coordinates":133},[134,135],-84.51439,39.12711,{"lat":135,"lon":134},[138,142],{"name":139,"role":42,"phone":140,"phoneExt":11,"email":141},"Brian Turpin, DO","513-636-2799","cancer@cchmc.org",{"name":139,"role":23,"phone":11,"phoneExt":11,"email":11},{"facility":144,"status":27,"city":145,"state":146,"zip":147,"country":31,"countryCode":32,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Children's Hospital of Philedephia","Philadelphia","Pennsylvania","19104",{"type":34,"coordinates":149},[150,151],-75.16362,39.95238,{"lat":151,"lon":150},[154,158],{"name":155,"role":42,"phone":156,"phoneExt":11,"email":157},"Shelby Brizzolara-Dove, BS","267-425-5544","CancerTrials@chop.edu",{"name":159,"role":23,"phone":11,"phoneExt":11,"email":11},"Theodore Laetsch, MD",{"facility":161,"status":66,"city":162,"state":163,"zip":164,"country":31,"countryCode":32,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Seattle Children's Hospital","Seattle","Washington","98105",{"type":34,"coordinates":166},[167,168],-122.33207,47.60621,{"lat":168,"lon":167},[171],{"name":172,"role":23,"phone":11,"phoneExt":11,"email":11},"Mark Fluchel, MD",{"facility":174,"status":27,"city":175,"state":176,"zip":177,"country":31,"countryCode":32,"cosmosGeoPoint":178,"geoPoint":182,"contacts":183},"University of Wisconsin Cancer Center","Madison","Wisconsin","53715",{"type":34,"coordinates":179},[180,181],-89.40123,43.07305,{"lat":181,"lon":180},[184,188],{"name":185,"role":42,"phone":186,"phoneExt":11,"email":187},"Jenny Weiland, BS","608-890-8070","pedshemoncresearch@g-groups.wisc.edu",{"name":189,"role":23,"phone":11,"phoneExt":11,"email":11},"Christian Capitini, MD",{"type":191,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100488618","phase-1-spearhead-3-pediatric-study-100488618",false,"NCT05642455","SPEARHEAD-3 Pediatric Study","A Phase 1\u002F2 Open Label, Basket Study to Assess the Safety, Tolerability and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects With MAGE-A4 Positive Tumors","Inclusion Criteria:\n\n* Subject has histologically confirmed diagnosis of any one of the following cancers: (A) Synovial Sarcoma (SS), (B) MPNST, (C) Neuroblastoma, or (D) Osteosarcoma (OS).\n* Age:\n\n(A) Synovial Sarcoma: 2 to 17 years (B) MPNST, Neuroblastoma and Osteosarcoma: 2 to 21 years\n\n* Body weight ≥ 10 kg\n* Must have previously received a systemic chemotherapy\n* Measurable disease prior to lymphodepletion according to RECIST v1.1 (or INCR, 2017 Neuroblastoma only).\n* HLA-A\\*02 positive\n* Tumor shows MAGE-A4 expression confirmed by central laboratory.\n* Performance Status:\n\n(A) Subjects ≥16: Eastern Cooperative Oncology Group (ECOG) 0 or 1 (B) Subjects 2 to 16: Lansky score ≥ 80\n\n• Subject has anticipated life expectancy of greater than 3 months in the opinion of the investigator.\n\nExclusion Criteria:\n\n* Positive for HLA-A\\*02:05 in either allele; or any A\\*02 having same protein sequence as HLA-A\\*02:05\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide.\n* History of autoimmune or immune mediated disease\n* Known central nervous system (CNS) metastases.\n* Other prior malignancy that is not considered by the Investigator to be in complete remission\n* Clinically significant cardiovascular disease\n* Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus\n* Pregnant or breastfeeding\n* Experiencing ongoing rapid disease progression that in the opinion of the Investigator significantly increases the subjects risk associated with treatment.","ALL","2 Years","21 Years",{"count":203,"type":204},20,"ESTIMATED","INTERVENTIONAL",[207,208],"PHASE1","PHASE2","This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.",[211,212,213,214],"Synovial Sarcoma","Malignant Peripheral Nerve Sheath Tumor (MPNST)","Neuroblastoma (NBL)","Osteosarcoma","2026-02-05",{"date":217,"type":218},"2026-02-09","ACTUAL",{"date":220,"type":218},"2023-09-01",{"date":222,"type":204},"2038-07-30",{"name":224,"class":6},"USWM CT, LLC",10]